Immunovant (IMVT) Accounts Payables (2019 - 2026)

Immunovant's Accounts Payables history runs 8 years deep, the most recent figure standing at $7.5 million for Q1 2026.

• Quarterly Accounts Payables fell 57.29% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.5 million (down 57.29% YoY) and the FY2026 annual result came in at $7.5 million, down 57.29% from the prior year.
• Accounts Payables was $7.5 million for Q1 2026 at Immunovant, down from $8.6 million in the prior quarter.
• Across five years, Accounts Payables topped out at $26.5 million in Q2 2023 and bottomed at $1.1 million in Q2 2022.
• A 5-year average of $11.0 million and a median of $7.8 million in 2025 frame the typical range for Accounts Payables.
• Peak annual rise in Accounts Payables reached 2382.08% in 2023, while the deepest fall reached 92.74% in 2023.
• Immunovant's Accounts Payables stood at $14.0 million in 2022, then slumped by 72.08% to $3.9 million in 2023, then jumped by 406.8% to $19.8 million in 2024, then tumbled by 56.52% to $8.6 million in 2025, then dropped by 12.48% to $7.5 million in 2026.
• Business Quant data shows IMVT's Accounts Payables at $7.5 million in Q1 2026, $8.6 million in Q4 2025, and $6.9 million in Q3 2025.